Microsomal Prostaglandin E Synthase-1 Expression by Aortic Smooth Muscle Cells Attenuates the Differentiated Phenotype
- 1 August 2016
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 68 (2) , 127-142
Abstract
The development of numerous types of cardiovascular disease is associated with alteration of the vascular smooth muscle cell (SMC) phenotype. We have previously shown that abdominal aortic aneurysm progression in a mouse model of the disease is associated with reduced differentiation of SMCs within the lesion and that cyclooxygenase-2 (COX-2) is critical to initiation and progression of the aneurysms. The current studies used human aortic SMC (hASMC) cultures to better characterize mechanisms responsible for COX-2-dependent modulation of the SMC phenotype. Depending on the culture conditions, hASMCs expressed multiple characteristics of a differentiated and contractile phenotype, or a dedifferentiated and secretory phenotype. The pharmacological inhibition of COX-2 promoted the differentiated phenotype, whereas treatment with the COX-2–derived metabolite prostaglandin E2 (PGE2) increased characteristics of the dedifferentiated phenotype. Furthermore, pharmacological inhibition or siRNA-mediated knockdown of microsomal prostaglandin E synthase-1 (mPGES-1), the enzyme that functions downstream of COX-2 during the synthesis of PGE2, significantly increased expression of characteristics of the differentiated SMC phenotype. Therefore, our findings suggest that COX-2 and mPGES-1–dependent synthesis of PGE2 contributes to a dedifferentiated hASMC phenotype and that mPGES-1 may provide a novel pharmacological target for treatment of cardiovascular diseases where altered SMC differentiation has a causative role.Keywords
This publication has 77 references indexed in Scilit:
- Cyclooxygenase-2 Inhibition Attenuates Abdominal Aortic Aneurysm Progression in Hyperlipidemic MicePLOS ONE, 2012
- Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cellsBlood, 2011
- Targeted Deletions of Cyclooxygenase-2 and Atherogenesis in MiceCirculation, 2010
- TGF-β suppresses the upregulation of MMP-2 by vascular smooth muscle cells in response to PDGF-BBAmerican Journal of Physiology-Cell Physiology, 2010
- Smooth muscle phenotypic modulation is an early event in aortic aneurysmsThe Journal of Thoracic and Cardiovascular Surgery, 2009
- Integrative genomics identifies DSCR1 (RCAN1) as a novel NFAT-dependent mediator of phenotypic modulation in vascular smooth muscle cellsHuman Molecular Genetics, 2009
- A novel anti-atherogenic role for COX-2—potential mechanism for the cardiovascular side effects of COX-2 inhibitorsProstaglandins & Other Lipid Mediators, 2007
- MYH11 mutations result in a distinct vascular pathology driven by insulin-like growth factor 1 and angiotensin IIHuman Molecular Genetics, 2007
- Deletion of microsomal prostaglandin E synthase-1 augments prostacyclin and retards atherogenesisProceedings of the National Academy of Sciences, 2006
- Inflammation and Matrix Metalloproteinases in the Enlarging Abdominal Aortic AneurysmArteriosclerosis, Thrombosis, and Vascular Biology, 1995